Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228752 | 1.00 | FOLH1 (0.48) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL15716271 | 1.00 | FOLH1 (0.48) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL16758733 | 0.92 | FOLH1 (0.51) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL28000849 | 0.87 | CTRB1 (0.52) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL28000850 | 0.87 | CTRB1 (0.52) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL10187034 | 0.86 | CTRB1 (0.59) | CA1CA2CA9SMN1; SMN2CTRB1 | |
| SCHEMBL23396215 | 0.85 | HTT (0.48) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL4206057 | 0.85 | HTT (0.48) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL1565052 | 0.85 | HTT (0.48) | FOLH1SLC1A1CA1CA2CA7 | |
| SCHEMBL3354066 | 0.84 | SMN1; SMN2 (0.47) | FOLH1CYP3A4MAPK1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| WO-2023125918-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028643-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | FOLH1 2117/4885SLC1A1 4139/4885CA1 3585/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | FOLH1 2762/4885SLC1A1 3378/4885CA1 3648/4885 |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | FOLH1 341/4885SLC1A1 3076/4885CA1 1168/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | FOLH1 341/4885SLC1A1 3076/4885CA1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.